期刊文献+

Progress in Chimeric Vector and Chimeric Gene Based Cardiovascular Gene Therapy 被引量:1

Progress in Chimeric Vector and Chimeric Gene Based Cardiovascular Gene Therapy
下载PDF
导出
摘要 Gene therapy for cardiovascular diseases has developed from preliminary animal experiments to clinical trials. However, vectors and target genes used currently in gene therapy are mainly focused on viral, nonviral vector and single target gene or monogene. Each vector system has a series of advantages and limitations. Chimeric vectors which combine the advantages of viral and nonviral vector, chimeric target genes which combine two or more target genes and novel gene delivery modes are being developed. In this article, we summarized the progress in chimeric vectors and chimeric genes based cardiovascular gene therapy, which including proliferative or occlusive vascular diseases such as atheroslerosis and restenosis, hypertonic vascular disease such as hypertension and cardiac diseases such as myocardium ischemia, dilated cardiomyopathy and heart failure, even heart transplantation. The development of chimeric vector, chimeric gene and their cardiovascular gene therapy is promising. Gene therapy for cardiovascular diseases has developed from preliminary animal experiments to clinical trials. Howewer, vectors and target genes used currently in gene therapy are mainly focused on viral, nonviral vector and single target gene or monogene. Each vector system has a series of advantages and limitations. Chimeric vectors which combine the advantages of viral and nonviral vector, chimeric target genes which combine two or more target genes and novel gene delivery modes are being developed. In this article, we summarized the progress in chimeric vectors and chimeric genes based cardiovascular gene therapy, which including proliferative or occlusive vascular diseases such as atheroslerosis and restenosis, hypertonic vascular disease such as hypertension and cardiac diseases such as myocardium ischemia, dilated cardiomyopathy and heart failure, even heart transplantation. The development of chimeric vector, chimeric gene and their cardiovascular gene therapy is promising.
出处 《中国分子心脏病学杂志》 CAS 2003年第6期344-350,共7页 Molecular Cardiology of China
关键词 心血管疾病 基因治疗 嵌合载体 妄想基因 chimeric vector chimeric gene gene therapy cardiovascular disease
  • 相关文献

参考文献2

二级参考文献12

  • 1[1]Rodriguez-Cruz E, Karpawich PP, Lieberman RA, et al.Biventricular pacing as alternative therapy for dilated cardiomyopathy associated with congenital heart disease. Pacing Clin Electrophysiol 2001; 24(2) :235-7.
  • 2[2]Li YY, Feng Y, McTiernan CF et al. Downregulation of matrix metalloproteinases and reduction in collagen damage in the failing human heart after support with left ventricular assist devices. Circulation 2001, 104(1):1147-52.
  • 3[3]Ohkusa T, Harada M, Hiro T, et al. Heart transplantation for dilated cardiomyopathy possibly caused by fulminant acute myocarditis: a case report. J Cardiol 2002; 39(1):39-46.
  • 4[4]Gradinac S, Popovic Z, Miric M, et al. Partial left ventriculectomy and limited heart transplantation availability. J Card Surg, 2001, 16(2): 165-9.
  • 5[6]Tomita S, Li RK, Weisel RD, et al. Autologous transplantation of bone marrow cells improves damaged heart function.Circulation 1999; 100(19 Suppl): Ⅱ 247-56.
  • 6[7]Orlic D, Kajstura J, Chimenti S, et al. Bone marrow cells regenerate infarcted myocardium. Nature 2001; 410 (6829):701-5.
  • 7[8]Hamano K, Li TS, Kobayashi T, et al. Angiogenesis induced by the implantation of self-bone marrow cells: a new material for therapeutic angiogenesis. Cell Transplant 2000; 9(3) :439-43.
  • 8[9]Gerber HP, Hillan KJ, Ryan AM, et al. VEGF is required for growth and survival in neonatal mice. Development 1999; 126 (6): 1149-59.
  • 9[10]Bellomo D, Headrick JP, Silins GU, et al. Mice lacking the vascular endothdial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia. Circ Res 2000; 86 (2): E29-35.
  • 10[11]Szilvassy SJ, Bass MJ, Van Zant G, et al. Organ-selective homing defines engraftment kinetics of murine hematopoietic stem cells and is compromised by Ex vivo expansion. Blood,1999, 93(5): 1557-66.

共引文献9

同被引文献6

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部